BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile-Reference-Cited by-同舟云学术

BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile

Published:2017-06-29 Issue:43 Volume:8 Page:74233-74243
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Alvarez Carolina¹,Tapia Teresa¹,Perez-Moreno Elisa¹,Gajardo-Meneses Patricia¹,Ruiz Catalina²,Rios Mabel³,Missarelli Claudio³,Silva Mariela³,Cruz Adolfo⁴,Matamala Luis⁵,Carvajal-Carmona Luis⁶,Camus Mauricio²,Carvallo Pilar¹

Affiliation:

1. Department of Cell and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile

2. Centro de Cáncer, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

3. Unidad de Patología Mamaria, Hospital Base de Valdivia, Valdivia, Chile

4. Unidad de Patología Mamaria, Hospital Barros Luco Trudeau, Santiago, Chile

5. Unidad de Patología Mamaria, Hospital Regional de Antofagasta, Antofagasta, Chile

6. Genome Center and Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, California, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review;Cancers;2023-12-21

2. Association of Germline Variation in Driver Genes with Breast Cancer Risk in Chilean Population;International Journal of Molecular Sciences;2023-11-08

3. Genotyping, sequencing and analysis of 140,000 adults from Mexico City;Nature;2023-10-11

4. BRCA1/2 potential founder variants in the Jordanian population: an opportunity for a customized screening panel;Hereditary Cancer in Clinical Practice;2023-07-03

5. Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients;Breast Cancer Research and Treatment;2023-03-29